J&J, Bavarian Nordic and GSK involved in upcoming Ebola vax trials; Researchers develop rheumatoid arthritis immunotherapy;

> Upcoming Ebola vaccine trials in Ghana will be led by Johnson & Johnson ($JNJ) and Bavarian Nordic in Phase I and GlaxoSmithKline ($GSK) in Phase II. Report

> Australia's University of Queensland researchers developed an immunotherapy for people with the most common form of rheumatoid arthritis. More

> Cellular Biomedicine Group ($CBMG) acquired from Blackbird Bio Finance a cancer vaccine to be used in a trial of non-small cell lung cancer. Release

> A cancer vaccine from Australia's Regenus, originally tried in dogs, will be used in 21 humans with advanced cancers who have exhausted all available treatment regimens. Report

Suggested Articles

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.

Experts are pushing for the introduction of J&J's vaccine in the response to the Ebola outbreak in the Democratic Republic of Congo.